EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy

Zhimin Zhang iD, Liubin Guo, Mengting Zhao, Hao Pan, Zhao Dong, Ling Wang, Xi Yang, Zhiping Zhang, Mengqiang Wu, Yujie Chang, Yacheng Yang, Linan Sun und 9 weitere

Journal of Medicinal Chemistry · 14.11.2024 · 67 (21) · 18682-18698

DOI: 10.1021/acs.jmedchem.4c01906 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.10.2024. Verfasst von Zhimin Zhang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Global Drug R&D Center, Huadong Medicine, Hangzhou 310011, P. R. China. Hauptthemen laut MEDLINE: Immunotherapy, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematopoietic progenitor kinase 1 (HPK1, MAP4K1), a serine/threonine (SER/THR) kinase, has been identified as a negative immune regulator of T-cell receptor signaling. Deprivation of the HPK1 function suppresses tumor growth, providing an attractive strategy for cancer immunotherapy. Herein, we present a novel PROTAC-based HPK1 degrader compound DD205-291 with high selectivity and potency. DD205-291 showed a dose-dependent inhibition of SLP-76 phosphorylation and an induction of IL-2 and IFN-γ. Compared with other inhibitors, DD205-291 exhibited good efficacy and a favorable safety profile in the MC38 model. Specifically, oral administration of DD205-291 at 0.5 mg/kg in combination with anti-PD1 resulted in significant suppression with a TGI value of 91.0%. Furthermore, DD205-291 exhibited a low risk of cardiotoxicity and a wide safety window. This research effort demonstrates that DD205-291 is a promising preclinical candidate (PCC) for potential mono- and comboimmunotherapy of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyProtein Serine-Threonine KinasesAnimalsHumansMiceAntineoplastic AgentsNeoplasmsCell Line, TumorPhosphorylationMice, Inbred C57BLDrug DiscoveryProtein Kinase InhibitorsStructure-Activity RelationshipProteolysis

Substanzen

Protein Serine-Threonine Kinaseshematopoietic progenitor kinase 1Antineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Global Drug R&D Center, Huadong Medicine, Hangzhou 310011, P. R. China.

ORCID-Profile: Zhimin Zhang

Zitieren

APA

Zhang, Z., Guo, L., Zhao, M., Pan, H., Dong, Z., Wang, L., Yang, X., Zhang, Z., Wu, M., Chang, Y., Yang, Y., Sun, L., Liu, S., Zhu, R., Zheng, H., Dai, X., Zhang, X., Jiang, C., Zhu, Z., …, & Liu, D. (2024). Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy. Journal of Medicinal Chemistry, 67(21), 18682-18698. https://doi.org/10.1021/acs.jmedchem.4c01906

Vancouver

Zhang Z, Guo L, Zhao M, Pan H, Dong Z, Wang L, et al. Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy. Journal of Medicinal Chemistry. 2024;67(21):18682-18698. doi:10.1021/acs.jmedchem.4c01906

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhimin and Guo, Liubin and Zhao, Mengting and Pan, Hao and Dong, Zhao and Wang, Ling and Yang, Xi and Zhang, Zhiping and Wu, Mengqiang and Chang, Yujie and Yang, Yacheng and Sun, Linan and Liu, Sirui and Zhu, Rongyao and Zheng, Haowen and Dai, Xinyu and Zhang, Xiaohua and Jiang, Chunhua and Zhu, Zhuangzhi and Zhang, Yuchen and Liu, Dongzhou},
  title = {Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {21},
  pages = {18682--18698},
  doi = {10.1021/acs.jmedchem.4c01906}
}
Kostenlos starten →